Annual report pursuant to Section 13 and 15(d)

Subsequent Events

v3.20.4
Subsequent Events
12 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsThe Company has evaluated subsequent events through the date on which the consolidated financial statements were available for issuance and noted that, other than the matters described below, the Company has not identified any significant events for which it needs to provide disclosure. On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN).